low molecular weight heparin & thromboprophylaxis
In patients undergoing surgery on hips or knees the risk of deep venous thrombosis (DVT) is 50-70%. In patients not receiving thromboprophylaxis 0.1-0.4% will die from pulmonary embolism.
Anticoagulant thromboprophylaxis treatments include:
- low-dose unfractionated heparin
- low-molecular-weight heparin
- recombinant hirudin
Despite these treatments 16-30% of hip replacement patients will develop venographically proven DVTs.
The thromboprophylactic dose of low molecular weight heparin is 5000 U twice a day.LMWH reduced the risk of DVT in patients post-total hip replacement by 31-79%. LMWH was as effective as full dose heparin but had a lower incidence of bleeding.
LMWH is also a safe and effective in prevention of DVT in patients undergoing total knee replacement.
Data suggests that a synthetic heparin analogue (fondaparinux) may be superior to LMWH.
- Weitz, JI (1997). Low-molecular-weight heparins. NEJM, 337, 689-698.
- The Columbus Investigators (1997). Low-molecular-weight heparin in the treatment of patients with venous thromboembolism. NEJM, 337, 657-62.
Last reviewed 01/2018